12 studies were found.

1.		Recruiting	Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected with HIV Condition: HIV Infections
2.		Terminated	Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Condition: Hematologic Malignancies
3.		Completed	A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients Condition: HIV Infections
4.		Completed	A Phase I Study of the Safety of Proleukin (aldesleukin) in Combination with Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis Conditions: Cytomegalovirus Retinitis; HIV Infections
5.		Completed	A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults Conditions: HIV Infections; HIV Seronegativity
6.		No longer recruiting	Proleukin in combination with Rituxan in patients with intermediate and high-grade Non-Hodgkin's lymphoma. Condition: Lymphoma, Non-Hodgkin
7.		No longer recruiting	Proleukin in Combination with Rituxan in Patients with Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments Condition: Lymphoma, Non-Hodgkin
8.		No longer recruiting	Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy Condition: HIV Infections
9.		Completed	Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals Condition: HIV Infections
10.		Recruiting	Tezacitabine and oxaliplatin for the treatment of patients with metastatic colorectal cancer Condition: Colorectal Neoplasms
11.		Recruiting	Tezacitabine with or without 5-Fluorouracil (5-FU) for advanced esophageal cancer or gastric cancer Conditions: Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma
12.		Recruiting	Tifacogin for the Treatment of Patients with Severe Community-Acquired Pneumonia Condition: Pneumonia